Rx Product News

Pharmacy Times, October 2013 Diabetes, Volume 79, Issue 10

Our round-up of the latest Rx products.

Marketed by: Forest Laboratories, Inc.

Indication: The FDA has approved Fetzima (levomilnacipran), a serotonin and norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Fetzima is not approved for the management of fibromyalgia. The recommended dose is 40 to 120 mg once daily with or without food. Dosing should be initiated by taking 20 mg once daily for 2 days. Capsules should be swallowed whole.

Dosage Form: Extended-release capsules: 20, 40, 80, and 120 mg

For More Information: https://fetzima.com

Epaned

Marketed by: Silvergate Pharmaceuticals, Inc

Indication: The FDA has approved Epaned (enalapril), an angiotensin-converting enzyme inhibitor for the treatment of hypertension in adults and children older than 1 month. The recommended initial dose in adults is 5 mg once daily, with a maximum dose of 40 mg/day. In children, the recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily.

Dosage Form: Powder for oral solution: 150 mg of enalapril maleate in a 150 mL bottle; reconstitution with 150 mL of ORA-SWEET SF results in a 1 mg/mL oral solution

For More Information: www.SilvergatePharma.com

Oseni

Marketed by: Takeda Pharmaceuticals America, Inc

Indication: The FDA has approved Oseni—a dipeptidyl peptidase-4 inhibitor and thiazolidinedione combination product—as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Oseni is not indicated for treating type 1 diabetes mellitus or diabetic ketoacidosis. The starting dose should be individualized to the patient, but a daily dose of alogliptin 25 mg and pioglitazone 45 mg should not be exceeded.

Dosage Form: Tablets (mg alogliptin/mg pioglitazone): 25/15, 25/30, 25/45, 12.5/15, 12.5/30, 12.5/45

For More Information: www.takeda.us/products/default.aspx

Marketed by: GlaxoSmithKline

Indication: The FDA has approved FluLaval Quadrivalent, a vaccine indicated for active immunization to prevent disease caused by influenza A subtype viruses and type B viruses in persons 3 years and older. The recommended dose in children 3 through 8 years of age who have not been vaccinated against influenza is 2 doses (0.5 mL each) at least 4 weeks apart. For more details, see the manufacturer’s prescribing information.

Dosage Form: Suspension for injection in 5-mL multidose vials containing ten 0.5-mL doses

For More Information: http://us.gsk.com/html/medicines/index.html#vaccineshttp://us.gsk.com/products/assets/us_flulaval_ quadrivalent.pdf